Stock Day Media

CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial

October 20, 2020October 20, 2020 Stock Day Media 132 Views covid19, cytodyn, DSMC, interimanalysis, Leronlimab, registrationaltrial

DSMC recommends CytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint DSMC

BioTech

CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines

October 13, 2020October 13, 2020 Stock Day Media 196 Views chiralpharma, cydy, cytodyn, FDA, Leronlimab, philippines

VANCOUVER, Washington, Oct. 12, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19

August 7, 2020August 7, 2020 Stock Day Media 269 Views covid19, cydy, cytodyn, hiv, Leronlimab

BLA-type submission planned this month in U.K. for HIV combination therapy with 350 mg weekly dose• COVID-19 Phase 2 topline report

BioTech

CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

July 6, 2020July 6, 2020 Stock Day Media 915 Views covid19, cydy, cytodyn, Leronlimab

This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of

BioTech

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

July 2, 2020July 2, 2020 Stock Day Media 894 Views cydy, Immuno-Oncology, Leronlimab, mechanism

VANCOUVER, Washington, July 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company

BioTech

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

May 18, 2020May 18, 2020 Stock Day Media 757 Views cydy, cytodyn, Leronlimab, phase3trial, remdesivir, threearmcomparitive

VANCOUVER, Washington, May 18, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19

April 15, 2020April 15, 2020 Stock Day Media 410 Views covid19, cydy, cytodyn, Leronlimab

VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

Leronlimab

CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial

CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines

CytoDyn’s Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’

After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.’s MHRA Accepts CytoDyn’s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms

CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19

CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S.

CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19

Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7